CoChat

Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future

Open access
Alomar, Muaed, Tawfiq, Ali M, Hassan, Nageeb, Palaian, Subish · 2020 · Therapeutic Advances in Drug Safety

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Background: To highlight the importance of spontaneous reporting programs in post marketing surveillance of medicines. Authors also aimed at providing various dimensions of spontaneous programs, including the strengths and weakness, and providing an insight on the future prospects of pharmacovigilance systems. Methods: Various literature related to post marketing surveillance and spontaneous reporting programs were reviewed and the relevant ones highlighting the strengths and weaknesses are summarized. A balance of information on strengths and weaknesses is listed. The health professionals’ awareness regarding existing spontaneous reporting programs is highlighted. Future prospects of pharmacovigilance are discussed. Results: Though beneficial, spontaneous reporting programs encounter several limitations and difficulties in diagnosing adverse drug reaction. Under-reporting and bias are major challenges. Online signal detection tools and innovative methods are needed to strengthen the spontaneous reporting programs. We provide the various issues to be considered while depending on spontaneous reporting programs as a method of post marketing surveillance. Conclusion: To strengthen the spontaneous reporting programs as an effective post marketing surveillance method, more awareness among health professionals and innovative strategies is needed. Integrating pharmacogenetic data can be a potential aspect of future pharmacovigilance. Plain language summary: Monitoring adverse effects of marketed medicines through reporting by healthcare professionals and its challenges and way forward Introduction: This article highlights the importance of safety monitoring of medicines after they are launched in the market, mainly through reporting by healthcare professionals. We also highlight the strengths and weaknesses, and provide an insight on the future prospects of pharmacovigilance systems. Methods: Various literature related to the topic were reviewed and the relevant ones highlighting the strengths and weaknesses are summarized. A balance of information on strengths and weaknesses is listed. Health professionals’ awareness regarding existing programs on reporting safety of medicines is highlighted. Results: Though beneficial, reporting of adverse effects by healthcare professionals who deal with patient lacks clarity in diagnosing the adverse effects. Under-reporting and bias are the major challenges. Online software is needed to strengthen reporting by healthcare professionals. We list the various issues to be considered while depending on healthcare professionals’ reporting of adverse effects as a method of post marketing surveillance. Conclusion: To strengthen medicine safety monitoring and reporting by healthcare professionals, more awareness among health professionals and innovative strategies are needed. Integrating the genetic data of patients can be beneficial in predicting adverse effects, therefore avoiding them and enhancing safe prescribing and dispensing by healthcare professionals.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/2042098620938595

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 58 · Cited by 272

Research works printed but not linked: 5

  1. World Health Organization, 2002, Safety of medicines: a guide to detecting and reporting adverse drug reactions: why health professionals need to take action
  2. Pain J, 2016, Proceedings of the 2nd workshop on noisy user-generated text, 94
  3. Bahri P, 2007, Pharmacovigilance, 51
  4. Uppsala Monitoring Centre, 2020, Uppsala Rep, 82, 4
  5. Sundaran S, 2013, WJPR, 2, 297

Metadata

Authors
Alomar, M., Tawfiq, A. M., Hassan, N., & Palaian, S.
Affiliations
Ajman University (AE)
Corresponding author
Alomar, Muaed
Venue
Therapeutic Advances in Drug Safety
Published
2020-01
Volume
11
Pages
2042098620938595-2042098620938595
ISSN
  • 2042-0986 (ISSN-L)
  • 2042-0994
OpenAlex
W3048905614
Cited by
272
References
58
Citations by year
2026: 59 · 2025: 68 · 2024: 57 · 2023: 39 · 2022: 25 · 2021: 17 · 2020: 2
FWCI
4.23
Type
journal article
Language
en
Open access
Locations
  • Therapeutic Advances in Drug Safety (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
  • Health Sciences › Medicine › Epidemiology › Data-Driven Disease Surveillance
Keywords
post-marketing surveillance, spontaneous reporting, pharmacovigilance, adverse drug reactions, underreporting, reporting bias, health professional awareness, pharmacogenetics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. https://app.cochat.ai/papers/10.1177/2042098620938595
The paper
Alomar, M., Tawfiq, A. M., Hassan, N., & Palaian, S. (2020). Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Therapeutic Advances in Drug Safety. https://doi.org/10.1177/2042098620938595

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.